Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Shen, Lin, Kato, Ken, Kim, Sung-Bae, Ajani, Jaffer A, Zhao, Kuaile, He, Zhiyong, Yu, Xinmin, Shu, Yongqian, Luo, Qi, Wang, Jufeng, Chen, Zhendong, Niu, Zuoxing, Zhang, Longzhen, Yi, Tienan, Sun, Jong-Mu, Chen, Jianhua, Yu, Guohua, Lin, Chen-Yuan, Hara, Hiroki, Bi, Qing, Satoh, Taroh, Pazo-Cid, Roberto, Arkenau, Hendrick-Tobias, Borg, Christophe, Lordick, Florian, Li, Liyun, Ding, Ningning, Tao, Aiyang, Shi, Jingwen, Van Cutsem, Eric
Published in Journal of clinical oncology (10.09.2022)
Published in Journal of clinical oncology (10.09.2022)
Get full text
Journal Article
Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)
Berry, Sneha, Giraldo, Nicolas, Nguyen, Peter, Green, Benjamin, Xu, Haiying, Ogurtsova, Aleksandra, Soni, Abha, Succaria, Farah, Wang, Daphne, Roberts, Charles, Stein, Julie, Engle, Elizabeth, Pardoll, Drew, Anders, Robert, Cottrell, Tricia, Taube, Janis M, Tran, Ben, Voskoboynik, Mark, Kuo, James, Bang, Yung-Lue, Chung, Hyun-Cheo, Ahn, Myung-Ju, Kim, Sang-We, Perera, Ayesh, Freeman, Daniel, Achour, Ikbel, Faggioni, Raffaella, Xiao, Feng, Ferte, Charles, Lemech, Charlotte, Meric-Bernstam, Funda, Werner, Theresa, Hodi, Stephen, Messersmith, Wells, Lewis, Nancy, Talluto, Craig, Dostalek, Mirek, Tao, Aiyang, McWhirter, Sarah, Trujillo, Damian, Luke, Jason, Xu, Chunxiao, BoMarelli, Qi, Jin, Qin, Guozhong, Yu, Huakui, Jenkins, Molly, Lo, Kin-Ming, Halle, Joern-Peter, Lan, Yan, Taylor, Matthew, Vogelzang, Nicholas, Cohn, Allen, Stepan, Daniel, Shumaker, Robert, Dutcus, Corina, Guo, Matthew, Schmidt, Emmett, Rasco, Drew, Brose, Marcia, Di Simone, Christopher, Jain, Sharad, Richards, Donald, Encarnacion, Carlos, Taylor, Matthew, Vogelzang, Nicholas, Mier, James, An, Jeongshin, Yang, Yeun-Yeoul, Lee, Won-Hee, Yang, Jinho, Kim, Jong-Kyu, Kim, Hyun Goo, Paek, Se Hyun, Lee, Jun Woo, Woo, Joohyun, Kim, Jong Bin, Kwon, Hyungju, Lim, Woosung, Paik, Nam Sun, Kim, Yoon-Keun, Moon, Byung-In, Janku, Filip, Tan, David, Martin-Liberal, Juan, Takahashi, Shunji, Geva, Ravit, Gucalp, Ayca, Chen, Xueying, Subramanian, Kulandayan, Mataraza, Jennifer, Wheler, Jennifer, Bedard, Philippe
Published in Journal for immunotherapy of cancer (13.02.2019)
Published in Journal for immunotherapy of cancer (13.02.2019)
Get full text
Journal Article
O1-1 Second-line tislelizumab vs chemotherapy in advanced or metastatic ESCC: RATIONALE 302 Japanese subgroup
Hara, Hiroki, Satoh, Taroh, Kojima, Takashi, Motoyama, Satoru, Tsushima, Takahiro, Sunakawa, Yu, Okada, Morihito, Tao, Aiyang, Ding, Ningning, Kato, Ken
Published in Annals of oncology (01.07.2022)
Published in Annals of oncology (01.07.2022)
Get full text
Journal Article
MO19-4 Impact of tislelizumab on health-related quality of life in Asian patients with esophageal squamous cell carcinoma
Kato, Ken, Van Cutsem, Eric, Ajani, Jaffer, Shen, Lin, Barnes, Gisoo, Ding, Ningning, Tao, Aiyang, Xia, Tianyu, Zhan, Lin, Kim, Sung-Bae
Published in Annals of oncology (01.11.2023)
Published in Annals of oncology (01.11.2023)
Get full text
Journal Article
Tislelizumab in advanced/metastatic esophageal squamous cell carcinoma: health-related quality of life in Asian patients
Kim, Sung-Bae, Van Cutsem, Eric, Ajani, Jaffer, Shen, Lin, Barnes, Gisoo, Ding, Ningning, Tao, Aiyang, Xia, Tianyu, Zhan, Lin, Kato, Ken
Published in Current medical research and opinion (2024)
Published in Current medical research and opinion (2024)
Get more information
Journal Article
Randomized, global, phase 3 study of tislelizumab (TIS) + chemotherapy (chemo) versus placebo (PBO) + chemo as first-line (1L) treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Non-Asia subgroup
Raymond, Eric, Hubner, Richard, Gotovkin, Evgeny, Wyrwicz, Lucjan, Van Cutsem, Eric, Jimenez-Fonseca, Paula, Pazo-Cid, Roberto, Xu, Jianming, Kato, Ken, Tao, Aiyang, Wang, Lei, Peng, Yanyan, Li, Liyun, Yoon, Harry H.
Published in Journal of clinical oncology (01.02.2023)
Published in Journal of clinical oncology (01.02.2023)
Get full text
Journal Article
Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma
Yoon, Harry H., Kato, Ken, Hubner, Richard, Raymond, Eric, Tao, Aiyang, Liu, Sumei, Qazi, Ibrahim, Xu, Jian-Ming
Published in Journal of clinical oncology (01.02.2020)
Published in Journal of clinical oncology (01.02.2020)
Get full text
Journal Article
Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup
Zhao, Kuaile, Kim, Sung-Bae, Kato, Ken, Hsu, Chih-Hung, Hu, Sheng, Wang, Feng, Kojima, Takashi, Kim, Young Saing, Van Cutsem, Eric, Ajani, Jaffer A., Li, Liyun, Ding, Ningning, Tao, Aiyang, Shen, Lin
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup
Zhao, Kuaile, Kim, Sung-Bae, Kato, Ken, Hsu, Chih-Hung, Hu, Sheng, Wang, Feng, Kojima, Takashi, Kim, Young Saing, Van Cutsem, Eric, Ajani, Jaffer A., Li, Liyun, Ding, Ningning, Tao, Aiyang, Shen, Lin
Published in Journal of clinical oncology (01.02.2022)
Published in Journal of clinical oncology (01.02.2022)
Get full text
Journal Article
RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma
Shen, Lin, Kato, Ken, Kim, Sung-Bae, Ajani, Jaffer A., Zhao, Kuaile, He, Zhiyong, Yu, Xinmin, Shu, Yongqian, Luo, Qi, Wang, Jufeng, Chen, Zhendong, Niu, Zuoxing, Sun, Jong Mu, Lin, Chen-Yuan, Hara, Hiroki, Pazo-Cid, Roberto, Borg, Christophe, Li, Liyun, Tao, Aiyang, Van Cutsem, Eric
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC
Chiappori, Alberto, Williams, Charles C., Creelan, Ben C., Tanvetyanon, Tawee, Gray, Jhanelle Elaine, Haura, Eric B., Thapa, Ram, Chen, Dung-Tsa, Beg, Amer A., Boyle, Theresa A., Bendiske, Jennifer, Morris, Erick, Tao, Aiyang, Hurtado, Felipe K., Manenti, Luigi, Castro, Julio, Antonia, Scott Joseph
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
Effects of Vitamin A Deficiency and Retinoic Acid Treatment on Expression of a Phosphoenolpyruvate Carboxykinase-Bovine Growth Hormone Gene in Transgenic Mice
Shin, D.J., Tao, A.Y., Mcgrane, M.M.
Published in Biochemical and biophysical research communications (15.08.1995)
Published in Biochemical and biophysical research communications (15.08.1995)
Get full text
Journal Article